Navigation Links
Cutting Phosphate May Protect Kidney Patients From Heart Trouble
Date:4/23/2008

High levels are major source of cardiovascular death risk in those with chronic disease

WEDNESDAY, April 23 (HealthDay News) -- Readily available phosphate-binding drugs could help prevent heart disease in people with chronic kidney disease (CKD), a new study finds.

Researchers at Washington University School of Medicine in St. Louis noted that patients with chronic kidney disease (CKD) are at high risk of death from cardiovascular disease, and that recent studies have shown that a high level of phosphate in the blood is a major source of cardiovascular death risk in these patients.

In tests on mice with CKD, the researchers found that high blood phosphate levels directly stimulate calcification of blood vessels and that phosphate-binding drugs can decrease this vascular calcification. This means drugs that reduce phosphate levels may help protect CKD patients from cardiovascular disease, the researchers said.

The study was published in the Journal of the American Society of Nephrology.

"One of the kidney's functions is to help maintain a constant balance of phosphate in the bloodstream," senior author Dr. Keith A. Hruska, director of the Division of Pediatric Nephrology and professor of pediatrics, medicine and of cell biology and physiology, said in a prepared statement.

"When kidney failure occurs, an excess of serum phosphate develops. It turns out that high phosphate serves as a signal that stimulates cells within blood vessel walls to become bone-forming cells and to deposit calcium crystals. That produces vascular stiffness that is a cause of cardiovascular mortality," Hruska explained.

Based on the evidence from this and other studies, the U.S. Food and Drug Administration recently decided to extend the label of phosphate-binding drugs on the market. These drugs -- calcium acetate (PhosLo), sevelamer (Renagel) and lanthanum carbonate (Fosrenol) -- will now be labeled to indicate they are approved for treatment of high serum phosphate levels in CKD patients.

About 19 million Americans have chronic kidney disease.

Hruska and his colleagues also found that a growth factor called BMP-7 (bone morphogenic factor-7) reduced phosphate levels and calcification of blood vessels in mice with CKD.

"Elderly osteoporosis patients and people with diabetes have high rates of cardiovascular disease and high levels of vascular calcification. So, our findings may have importance even beyond patients with CKD," study co-author Dr. Suresh Mathew, an instructor in pediatrics, said in a prepared statement.

More information

The American Academy of Family Physicians has more about CKD.



-- Robert Preidt



SOURCE: Washington University School of Medicine in St. Louis, news release, April 17, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. RIVAs Cutting Edge Technology To Help Intermountain Healthcare Enhance Medication Delivery Safety
2. Billians HealthDATA(R) Continues to Delight Their Customers with Comprehensive Cutting Edge Healthcare Market Intelligence
3. Cutting Back on Salt Cuts Down on Sodas With Kids
4. Verizon teams with MCG to test cutting-edge technology
5. Cutting caffeine may help control diabetes
6. New Democracy Corps Battleground Poll of Swing Districts Finds Strong, Bi-Partisan Opposition to Cutting Medicare-Funded Nursing Home Care
7. FDA Mulls Cutting Salt in Processed Foods
8. Financial incentives may hold key to cutting child malaria deaths
9. Cutting Edge CyberKnife Cancer Treatment Center to Open in Tampa Bay Area
10. The era of global aging: GSA showcases cutting-edge San Francisco meeting topics
11. Fern Tree, The Spa at Half Moon, Jamaicas Premier Spa, Opens With Ceremonial Ribbon Cutting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... ... self-service technology that runs on the Posiflex XT-series of touch screen terminals. Both ... HIMSS17 in Orlando, Florida. The terminal provider Posiflex is helping to bridge ...
(Date:2/20/2017)... , ... February 20, 2017 , ... ... welcomes you to stop by for a visit this week at HIMSS 2017 ... and executives from around the globe. Sensogram will be featured in the conference’s ...
(Date:2/20/2017)... Houston, TX (PRWEB) , ... February 20, 2017 ... ... he is now offering a full range of emergency dental care at his ... teeth and gums. When patients experience dental emergencies, they are at risk for ...
(Date:2/20/2017)... Orlando, FL (PRWEB) , ... February 20, 2017 ... ... company for eye care providers and health plan partners, announced during the 2017 ... the organization’s success enhancing care coordination for diabetic patients and integrating eye ...
(Date:2/19/2017)... (PRWEB) , ... February 19, 2017 , ... Braun Industries ... JEMS Conference & Exposition, the event will take place February 23-25, 2017 at the ... will be in Booth #909 with three new ambulances on display. ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , Feb. 17, 2017   FormFast , ... announced a new partnership with Engage , one ... United States . FormFast will serve as the ... Engage,s implementations with MEDITECH .  ... essential functionality to complement and enhance the electronic health ...
(Date:2/17/2017)...  BioDigital, Inc., creators of the BioDigital Human ... body mapping technology with eClinicalWorks, a privately held ... be used to capture and present dermatology exam ... body. BioDigital pilots show using a body to ... the precision of clinical annotations compared to standard ...
(Date:2/17/2017)... YORK , Feb. 17, 2017  Noble Capital ... on ESSA Pharma Inc. (Nasdaq: EPIX ). ... Research, Kumar Raja , PhD. ESSA ... for castration resistant prostate cancer (CRPC). Its lead compound ... blocks the amino-terminal domain of the androgen receptor, thereby ...
Breaking Medicine Technology: